These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 17317439

  • 1. Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).
    Campanozzi MD, Casali E, Neviani F, Martini E, Neri M.
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():91-6. PubMed ID: 17317439
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
    Mossello E, Tonon E, Caleri V, Tilli S, Cantini C, Cavallini MC, Bencini F, Mecacci R, Marini M, Bardelli F, Sarcone E, Razzi E, Biagini CA, Masotti G.
    Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors.
    Rozzini L, Costardi D, Chilovi BV, Franzoni S, Trabucchi M, Padovani A.
    Int J Geriatr Psychiatry; 2007 Apr; 22(4):356-60. PubMed ID: 17117398
    [Abstract] [Full Text] [Related]

  • 4. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
    López-Pousa S, Turon-Estrada A, Garre-Olmo J, Pericot-Nierga I, Lozano-Gallego M, Vilalta-Franch M, Hernández-Ferràndiz M, Morante-Muñoz V, Isern-Vila A, Gelada-Batlle E, Majó-Llopart J.
    Dement Geriatr Cogn Disord; 2005 Apr; 19(4):189-95. PubMed ID: 15677866
    [Abstract] [Full Text] [Related]

  • 5. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW, Yik PY, Mok W, Chung CP.
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [Abstract] [Full Text] [Related]

  • 6. Influence of cognitive impairment and comorbidity on disability in hospitalized elderly patients.
    Orsitto G, Cascavilla L, Franceschi M, Aloia RM, Greco A, Paris F, Seripa D, Pilotto A.
    J Nutr Health Aging; 2005 Mar; 9(3):194-8. PubMed ID: 15864400
    [Abstract] [Full Text] [Related]

  • 7. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M.
    J Alzheimers Dis; 2013 Mar; 35(2):349-61. PubMed ID: 23411693
    [Abstract] [Full Text] [Related]

  • 8. One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.
    Borkowska A, Ziolkowska-Kochan M, Rybakowski JK.
    Hum Psychopharmacol; 2005 Aug; 20(6):409-14. PubMed ID: 15991260
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A retrospective pilot study on the development of cognitive, behavioral and functional disorders in a sample of patients with early dementia of Alzheimer type.
    Coin A, Najjar M, Catanzaro S, Orru G, Sampietro S, Sergi G, Manzato E, Perissinotto E, Rinaldi G, Sarti S, Imoscopi A, Ruggiero E, Girardi A.
    Arch Gerontol Geriatr; 2009 Aug; 49 Suppl 1():35-8. PubMed ID: 19836614
    [Abstract] [Full Text] [Related]

  • 11. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.
    Freund-Levi Y, Basun H, Cederholm T, Faxén-Irving G, Garlind A, Grut M, Vedin I, Palmblad J, Wahlund LO, Eriksdotter-Jönhagen M.
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):161-9. PubMed ID: 17582225
    [Abstract] [Full Text] [Related]

  • 12. Realistic expectations for treatment success in Alzheimer's disease.
    Geldmacher DS, Frolich L, Doody RS, Erkinjuntti T, Vellas B, Jones RW, Banerjee S, Lin P, Sano M.
    J Nutr Health Aging; 2006 Feb; 10(5):417-29. PubMed ID: 17066215
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cognitive predictors of donepezil therapy response in Alzheimer disease.
    Saumier D, Murtha S, Bergman H, Phillips N, Whitehead V, Chertkow H.
    Dement Geriatr Cogn Disord; 2007 Feb; 24(1):28-35. PubMed ID: 17495473
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
    Wobrock T, Retz-Junginger P, Retz W, Supprian T, Rösler M.
    Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.